← Leaderboards
Christopher H Van Dyck
Cognition Therapeutics, Inc.
$43,230,259
Attributed
$97,675,910
Total exposure
12
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $31.2M · FY2008–25$50M$37.5M$25M$12.5M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$118,392,078 · 13
By mechanism
R01$79,292,126 · 7
P30$25,704,024 · 3
UH3$8,497,621 · 1
UH2$2,885,426 · 1
P50$2,012,881 · 1
Top collaborators
- Stephen M Strittmatter9 shared
- Yiyun Henry Huang5 shared
- Paul S. Aisen4 shared
- Richard E Carson4 shared
- Anthony O Caggiano3 shared
- Haakon Berge Nygaard3 shared
- Susan M Catalano1 shared
- Christopher A. Gaiteri1 shared
Most similar at Cognition Therapeutics, Inc.
Same institution · by research overlap
- Paul S. Aisen$209,920,520
- Anthony O Caggiano$51,394,003
- Susan M Catalano$36,630,926
- Nicholas John Izzo$4,437,830
- Mary E Hamby$9,832,688
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposS DiseaseBiological MarkersSynapsesBrainDementiaPathogenesisImpaired CognitionAutopsyPre-ClinicalDiagnosticNerve DegenerationMild Cognitive ImpairmentFuturePositron-Emission TomographyMonitorNeuronsAmyloid Beta-ProteinPathologyProteinsSerumImageCollaborationsTau Proteins
Grant awards (44)
Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 Months$11,955,061
R01 · FY2025 · AG
Yale Alzheimer Disease Research Center$4,760,911
P30 · FY2025 · AG
Clinical Core$1,045,486
P30 · FY2025 · AG · contact PI
Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 Months$13,127,747
R01 · FY2024 · AG
Yale Alzheimer Disease Research Center$3,170,528
P30 · FY2024 · AG
Clinical Core$812,764
P30 · FY2024 · AG · contact PI
Validation of Fluorine-18 radioligand for PET imaging of synaptic density in Alzheimer's disease$764,364
R01 · FY2024 · AG
Yale Alzheimer Disease Research Center$3,182,375
P30 · FY2023 · AG
Clinical Core$770,283
P30 · FY2023 · AG · contact PI
Validation of Fluorine-18 radioligand for PET imaging of synaptic density in Alzheimer's disease$764,364
R01 · FY2023 · AG
Yale Alzheimer Disease Research Center$3,193,057
P30 · FY2022 · AG
PET Imaging of SV2A and Other Biomarkers in Alzheimer's Disease$1,108,088
R01 · FY2022 · AG · contact PI
Clinical Core$777,754
P30 · FY2022 · AG · contact PI
Validation of Fluorine-18 radioligand for PET imaging of synaptic density in Alzheimer's disease$755,989
R01 · FY2022 · AG
Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 Months$14,619,478
R01 · FY2021 · AG
Yale Alzheimer Disease Research Center$3,203,339
P30 · FY2021 · AG
PET Imaging of SV2A and Other Biomarkers in Alzheimer's Disease$1,108,088
R01 · FY2021 · AG · contact PI
Clinical Core$785,944
P30 · FY2021 · AG · contact PI
Validation of Fluorine-18 radioligand for PET imaging of synaptic density in Alzheimer's disease$764,364
R01 · FY2021 · AG
Molecular Networks Underlying Resilience to Alzheimer's Disease Among APOE E4 Carriers$761,628
R01 · FY2021 · AG
Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 Months$24,533,829
R01 · FY2020 · AG
Yale Alzheimer Disease Research Center$3,205,958
P30 · FY2020 · AG
PET Imaging of SV2A and Other Biomarkers in Alzheimer's Disease$1,108,088
R01 · FY2020 · AG · contact PI
Validation of Fluorine-18 radioligand for PET imaging of synaptic density in Alzheimer's disease$814,874
R01 · FY2020 · AG
Clinical Core$795,625
P30 · FY2020 · AG · contact PI
PET Imaging of Synaptic Density in Alzheimers Disease$765,291
R01 · FY2020 · AG
PET Imaging of SV2A and Other Biomarkers in Alzheimer's Disease$1,108,088
R01 · FY2019 · AG · contact PI
PET Imaging of Synaptic Density in Alzheimers Disease$779,436
R01 · FY2019 · AG
Clinical Core$424,835
P50 · FY2019 · AG · contact PI
PET Imaging of SV2A and Other Biomarkers in Alzheimer's Disease$1,108,088
R01 · FY2018 · AG · contact PI
PET Imaging of Synaptic Density in Alzheimers Disease$814,985
R01 · FY2018 · AG
Clinical Core$394,285
P50 · FY2018 · AG · contact PI
PET Imaging of Synaptic Density in Alzheimers Disease$826,581
R01 · FY2017 · AG
Clinical Core$397,674
P50 · FY2017 · AG · contact PI
Fyn Inhibition by AZD0530 for Alzheimers Disease$2,590,082
UH3 · FY2016 · TR
Clinical Core$397,241
P50 · FY2016 · AG · contact PI
Clinical Core$398,846
P50 · FY2015 · AG · contact PI
Fyn Inhibition by AZD0530 for Alzheimers Disease$5,907,539
UH3 · FY2014 · TR
Fyn Inhibition by AZD0530 for Alzheimers Disease$2,885,426
UH2 · FY2013 · TR
Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects$381,025
R01 · FY2010 · AG · contact PI
Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects$376,701
R01 · FY2009 · AG · contact PI
Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects$388,041
R01 · FY2008 · AG · contact PI
SEROTONIN 5HT2A RECEPTORS IN DEPRESSION$283,088
R01 · FY2002 · MH
SEROTONIN 5HT2A RECEPTORS IN DEPRESSION$274,840
R01 · FY2001 · MH